How famotidine affects taletrectinib in healthy adults
Treatments studied
This study checks if taking famotidine (a common stomach acid reducer) changes how the body absorbs taletrectinib, an experimental cancer drug. Healthy volunteers take both drugs to see if they interact. This helps doctors know how to dose taletrectinib in future studies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old.
- You are generally healthy with no major medical conditions.
- You weigh more than 110 pounds (50 kg) and have a body mass index (BMI) between 19 and 26.
- You are willing to avoid certain foods and drinks (like grapefruit, caffeine, alcohol) and strenuous exercise during the study.
- You agree to use effective birth control (if applicable) and not donate sperm or eggs.
- You have not taken certain medications or supplements recently and have no history of drug or alcohol abuse.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the drug taletrectinib works for people with a specific type of advanced lung cancer (ROS1-positive NSCLC) whose cancer has gotten worse after treatment with the drug entrectinib. It aims to help doctors understand real-world outcomes for these patients.
This study compares a new targeted therapy pill (taletrectinib) to standard treatments for people with advanced ROS1-positive lung cancer. The goal is to see if taletrectinib works better at shrinking tumors and delaying cancer growth.
This trial checks how a new cancer drug (sevabertinib) affects levels of a common diabetes medicine (metformin) in healthy adults. It helps doctors understand how to dose both drugs safely when used together.
This trial is for healthy volunteers to see how the study drug taladegib (ENV-101) interacts with other medicines in the body. It will help researchers understand how the drug is absorbed and processed, which is important for future studies in patients.
This trial tests whether taletrectinib (a targeted pill) can help prevent lung cancer from coming back after surgery in people whose tumors have a ROS1 gene change. You would take either taletrectinib or a placebo (inactive pill) for about a year after surgery.
This study gathers real-world experience with the targeted drug taletrectinib for people with a specific type of advanced lung cancer (ROS1-positive) that has spread to the brain. Participation may help doctors better understand how well the drug works in everyday practice.
Hear when a new Healthy Adult Participants trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.